QualityDipStocks / Health Care · Pharmaceuticals
Nurix Therapeutics Common stock NRIX
Outside our quality screen, so we don’t track its dips. It’s 8% below its 52-week high.
Outside our quality screen. No fair value estimate for now: the model’s result is too extreme to stand behind.
Worth knowing
- FCF yield 12%, top 6% of the 1145 we measure
- Operating margin 41%, top 5% of the 1288 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $25.19price +2%
- Off 52-wk high
- −8%
- Risk vs market
- Above marketbeta 1.27
5 bullish · 1 bearish See why
Repriced or dip?
Near its high
The price is 8% below its 52-week high (Aug 19), but the business held up: revenue +1809.2%, earnings per share turned to a profit, free cash flow −$305M → $370M, turned positive.
Some numbers held up (revenue +1809.2%, earnings per share turned to a profit, free cash flow −$305M → $370M, turned positive), others slipped (shares outstanding more shares, each owns less). The price is 8% below its 52-week high.
The price is 8% below its 52-week high, and the business changed too: shares outstanding more shares, each owns less.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
Today about −9%. The last 3 years delivered 30%/yr (revenue).
Dashed line: what the last 3 years delivered, 30%/yr (revenue)
| High | Now | |
|---|---|---|
| Price | $27.79Aug 19 | $25.70 |
| Implied growth | n/a | −9% |
| P/E | n/a | 10.1× |
| P/FCF | — | 8.1× |
What this means: the higher the implied growth, the more the price already counts on. If today's number sits well below what the business has delivered, the market expects less than its track record.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
Estimate unreliable for NRIX: the model gives 282% above the price, more than we can stand behind (usually peak-cycle cash flow, heavy debt, or cash flows that include customer or loan balances). We’d rather show nothing than a made-up number.
What the price implies To be worth today’s price, NRIX’s free cash flow would need to shrink about 9% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much NRIX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 4.3× the S&P 500’s.
- Beta vs S&P 500
- 1.27
- Volatility
- 55% vs 13% SPY
- Correlation SPY
- 0.30
- Correlation QQQ
- 0.29
How it ranks
Where NRIX stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 2 of 3 measures
- Free cash flow yield12% · free cash flow vs market capTop 5%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Operating margin41% · of sales kept as operating profitTop 5%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $25.19 · FCF value $52.78
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationFree-cash-flow yield of 12.4% (price / FCF 8.1×): $370M of free cash in the last 12 months.
GrowthSales compounded 30% a year from FY2022 to FY2025.
ValuationP/E of 10.1× vs a 29.0× median for the 135 Health Care companies we cover.
ProfitabilityReturn on equity of 44% over the last 12 months, up 23 points in two years.
ProfitabilityOperating margin of 41% over the last 12 months.
Top bearish points 1 of 5
Cash returnsShare count up 38.0% in a year: existing holders are being diluted.
All fundamentals
P/E 10.1 · FCF yield 12.4% · ROE 44%
Valuation
- P/E
- 10.1×Health Care median 29.0×
- Price / FCF
- 8.1×
- FCF yield
- 12.4%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 4.25×
- Price / book
- 3.08×
- Market cap
- $3.0Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $702M
- Sales growth, 12 months
- n/an/m: revenue a year ago near zero
- Sales growth, 3 yrs
- +29.5%/yrfrom FY2022
- Diluted EPS, 12 months
- $2.43
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $295M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 41.3%
- Net margin
- 42.0%
- FCF margin
- 52.7%
- Return on equity
- 44%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $720M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $370M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +38.0%diluted shares vs a year ago
- Stock-based comp
- $41M
Trailing 12 months to Aug 31, 2026; balance sheet at Aug 31, 2026. From Nurix Therapeutics Common stock’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.2B · Sales +8426%
- Free cash flow, 12 months$0.2B
- Free-cash-flow yield12.4%
- Free-cash-flow margin33%
- Gross margin52%
- Operating margin83%
- Return on equity44%
- Sales growth (latest quarter vs year-ago quarter)+8426%
- Net debt / EBITDA−3.3×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $25.70
- 52-wk lowlowest close, 1 year$12.17−52.6%
- Market Valueavg paid since Oct 13$25.19−2.0%
- PriceMon Nov 2 close$25.70you are here
- 52-wk highhighest close, 1 year$27.79+8.1%
Momentum & 52-week range
RSI 54 · 5 days +0.6%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
NRIX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Nurix Therapeutics Common stock in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.